(Q40464939)

English

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.

scientific article published on December 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. (English)

1 reference

Europe PubMed Central

20 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ivana N M Micallef

1

1 reference

Europe PubMed Central

20 September 2017

Brad S Kahl

2

1 reference

Europe PubMed Central

20 September 2017

Matthew J Maurer

3

1 reference

Europe PubMed Central

20 September 2017

Ahmet Dogan

4

1 reference

Europe PubMed Central

20 September 2017

Stephen M Ansell

5

1 reference

Europe PubMed Central

20 September 2017

Joseph P Colgan

6

1 reference

Europe PubMed Central

20 September 2017

Susan Geyer

7

1 reference

Europe PubMed Central

20 September 2017

David J Inwards

8

1 reference

Europe PubMed Central

20 September 2017

William L White

9

1 reference

Europe PubMed Central

20 September 2017

Thomas M Habermann

10

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

1 December 2006

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

107

1 reference

Europe PubMed Central

20 September 2017

12

1 reference

Europe PubMed Central

20 September 2017

2826-2832

1 reference

Europe PubMed Central

20 September 2017

Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of GITR in activation response of T lymphocytes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of plasma immunoglobulin level on antibody synthesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Late-onset neutropenia following rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22342

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22342

1 reference

Europe PubMed Central

20 September 2017

release_ajzvre6sozgzxfop4ixfs7wlsq

1 reference

https://api.fatcat.wiki/v0/release/ajzvre6sozgzxfop4ixfs7wlsq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40464939&oldid=1841447623"